Dr. Michael Triplett is co-founder, Chairman of Armatus Bio, Inc., a multi-asset gene and cell therapy company based in Columbus, Ohio developing next generation therapies for neuromuscular diseases, neurodegenerative diseases, and cancer. Dr. Triplett is co-founder and co-Chairman of Clarametyx Biosciences, Inc., an early-stage infectious disease company pursuing paradigm shifting therapeutics and vaccines for the treatment and prevention of bacterial biofilm mediated diseases, after serving as founding President and CEO. Dr. Triplett co-founded and served as President and CEO of Myonexus Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-girdle muscular dystrophies acquired by Sarepta Therapeutics for >$225 million in April 2019.